Medical News

RSS

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Higher case volume associated with better outcomes of cardiac surgery: Study

A new analysis led by researchers at UCSF shows that avoiding lowest-volume hospitals and maximizing adherence to quality care processes are both effective approaches to reducing costs associated with coronary bypass surgery.

30 Jul 2010

Physicians Practice to hold virtual conference and exhibition for physicians, administrators

Physicians Practice, a division of UBM Medica, will hold Physicians Practice LIVE, a virtual conference and exhibition for physicians and administrators, for the second time this year on September 22. This exciting event will provide a full day of practice management seminars, networking with colleagues and industry experts, and an opportunity to see the latest in practice management products and services, all for free. The virtual learning environment gives attendees a cost-effective way to get crucial practice management information without having to leave their office.

30 Jul 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

HMS second-quarter net income increases to $9.1 million

HMS today announced its financial results for the second quarter of 2010.

30 Jul 2010

Despite all advancements in melanoma diagnosis, rapid treatment remains critical: Report

Twenty-five years after publishing the mnemonic "ABCD" to facilitate the early diagnosis of melanoma, the group who came up with that moniker says early detection remains a key factor in lowering mortality from malignant melanoma. Darrell S. Rigel, M.D. and colleagues from the Ronald O. Perelman Department of Dermatology at New York University School of Medicine say that, despite all of the advances in melanoma diagnosis, timely recognition, detection, and rapid treatment of melanoma remain critical.

30 Jul 2010

Volcano second-quarter revenues increase 36% to record $73.5 million

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.

30 Jul 2010

VAPAHCS acquires 15 Zargis Cardioscan systems

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that the VA Palo Alto Health Care System, a northern California based hospital group that is part of The Department of Veterans Affairs nationwide network of hospitals, recently purchased 15 Zargis Cardioscan systems.

30 Jul 2010

Down the silk road of the future

The Science paper notes that the development of silk hydrogels, films, fibers and sponges is making possible advances in photonics and optics, nanotechnology, electronics, adhesives and microfluidics, as well as engineering of bone and ligaments. Because silk fiber formation does not rely on complex or toxic chemistries, such materials are biologically and environmentally friendly, even able to integrate with living systems.

30 Jul 2010

Scientist examines relationship between stress of human isolation, immune system

A remote Canadian island is being used to simulate isolated space flight conditions for a NASA-funded medical research study that could produce important information to assist astronauts in potential long duration flights to Mars or an asteroid.

30 Jul 2010

McKesson first-quarter revenues increase to $27.5 billion

McKesson Corporation today reported that revenues for the first quarter ended June 30, 2010 were $27.5 billion compared to $26.7 billion a year ago. First-quarter earnings per diluted share was $1.10 compared to $1.06 per diluted share a year ago.

30 Jul 2010

First Edition: July 30, 2010

In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.

30 Jul 2010

FDA clears Hotspur's new balloon dilatation and embolectomy catheters

Hotspur Technologies, Inc. announced today that it has received FDA clearance for the first three commercial products in its portfolio. These products are based on Hotspur's unique and groundbreaking technology that makes dialysis access interventional and peripheral vascular procedures that open blood vessels less expensive, more efficient, and less invasive for patients.

30 Jul 2010

New bill that incorporates dentistry into federal disaster response framework passed

A bill that would incorporate dentistry into the federal disaster response framework unanimously passed the House Committee on Energy and Commerce this week. Introduced by Rep. Bart Stupak (D-Mich.), the Dental Emergency Responder Act (H.R. 903), the American Dental Association has for several years lobbied Congress vigorously to pass the bill.

30 Jul 2010

Partners in ENIAC project announce details of multinational/multidisciplinary program

The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.

30 Jul 2010

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

A recent study from researchers at Massachusetts General Hospital and University of Michigan provides the first direct evidence of linkage between elevated intrinsic (resting-state) brain connectivity and spontaneous pain intensity in patients with fibromyalgia (FM). This research shows an interaction of multiple brain networks, offering greater understanding of how pain arises. Details of the study appear online and in the August issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

Anadys Pharmaceuticals reports SVR12 data for ANA598

Anadys Pharmaceuticals, Inc. today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.

30 Jul 2010

Exoskeletons, powered prostheses and optical sensory devices market to exceed $877 million in 2020: Study

Lockheed Martin announced recently that it has received a $1.1-million contract from the US Army for human trials and evaluation of its advanced ruggedized Human Universal Load Carrier (HULC) exoskeleton, "designed to augment soldiers' strength and endurance, as well as reduce load carriage injuries."

30 Jul 2010

Amerigroup second-quarter total revenues increase 11.3% to $1.4 billion

Amerigroup Corporation today announced that net income for the second quarter of 2010 was $67.2 million, or $1.31 per diluted share, versus net income of $49.6 million, or $0.94 per diluted share, for the second quarter of 2009. Second quarter of 2009 results were positively impacted by a tax adjustment of $0.43 per diluted share related to litigation settled in 2008. Excluding the tax adjustment, second quarter of 2009 net income would have been $27.2 million, or $0.51 per diluted share.

30 Jul 2010

Medical News

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Higher case volume associated with better outcomes of cardiac surgery: Study

Physicians Practice to hold virtual conference and exhibition for physicians, administrators

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

HMS second-quarter net income increases to $9.1 million

Despite all advancements in melanoma diagnosis, rapid treatment remains critical: Report

Volcano second-quarter revenues increase 36% to record $73.5 million

VAPAHCS acquires 15 Zargis Cardioscan systems

Down the silk road of the future

Scientist examines relationship between stress of human isolation, immune system

McKesson first-quarter revenues increase to $27.5 billion

First Edition: July 30, 2010

FDA clears Hotspur's new balloon dilatation and embolectomy catheters

New bill that incorporates dentistry into federal disaster response framework passed

Partners in ENIAC project announce details of multinational/multidisciplinary program

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Anadys Pharmaceuticals reports SVR12 data for ANA598

Exoskeletons, powered prostheses and optical sensory devices market to exceed $877 million in 2020: Study

Amerigroup second-quarter total revenues increase 11.3% to $1.4 billion

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Latest News